FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions.

doi:10.1158/1078-0432.CCR-20-3558

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2021

Bradford Diana, Larkins Erin, Mushti Sirisha L, Rodriguez Lisa, Skinner Amy M, Helms Whitney S, Price Lauren S L, Zirkelbach Jeanne Fourie, Li Yangbing, Liu Jiang, Charlab Rosane, Turcu Francisca Reyes, Liang Dun, Ghosh Soma, Roscoe Donna, Philip Reena, Zack-Taylor Autumn, Tang Shenghui, Kluetz Paul G, Beaver Julia A, Pazdur Richard, Theoret Marc R, Singh Harpreet

Abstract excerpt

On May 8, 2020, the FDA granted accelerated approval to selpercatinib for (i) adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), (ii) adult and pediatric patients ≥12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy, and (iii) adult and pediatric patients ≥12 years of age with advanced or metastatic RET fusion-positive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase I as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase II as Topic

Share to Drug Approval

Share to Multicenter Studies as Topic

Share to Oncogene Proteins, Fusion

Share to Proto-Oncogene Proteins c-ret

Share to Pyrazoles

Share to United States Food and Drug Administration

Source

Open in PubMed

Identifiers

PMID: 33239432
DOI: 10.1158/1078-0432.CCR-20-3558

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions.PMID 33239432Read ↗

Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.Semantic proximity Read ↗

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Selpercatinib in the treatment of thyroid cancer.Semantic proximity Read ↗

FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions.Semantic proximity Read ↗

Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.Semantic proximity Read ↗

RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.Semantic proximity Read ↗

Targeting RET alterations in cancer: Recent progress and future directions.Semantic proximity Read ↗

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.Semantic proximity Read ↗

Targeting RET alterations in non-small cell lung cancer.Semantic proximity Read ↗

Treatment of non–small cell lung cancer with RET rearrangementsSemantic proximity Read ↗

RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.Semantic proximity Read ↗

Long-term safety of selpercatinib for Rearranged during transfection ( RET) -activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over timeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.